Data / Companies / DNA
Ginkgo Bioworks Holdings, Inc.NYSE
DNA-US · CIK 0001830214 · Biological Products, (No Diagnostic Substances)
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$20M$40M$60M$80M$100M
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $20.2M | -$46.7M | -0.75 |
| Q1 FY2026 | $19.5M | -$82.6M | -1.39 |
| Q4 FY2025 | $33.4M | -$80.8M | -1.41 |
| Q3 FY2025 | $38.8M | -$80.8M | -1.45 |
Newest filings
All 265| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 8-K | 29 Oct 2026 | 29 Oct, 4:06 PM | |
| 10-Q | 6 Aug 2026 | ||
| 8-K | 5 Aug 2026 | ||
| 8-K | 30 Jul 2026 | ||
| 8-K | 12 Jun 2026 | ||
| 10-Q | 7 May 2026 | ||
| 8-K | 7 May 2026 | ||
| ARS | 29 Apr 2026 |
Description
- Ticker
- DNA-US
- Exchange
- NYSE
- Index
- –
- Industry
- Biological Products, (No Diagnostic Substances)
- SIC division
- Manufacturing
- CIK
- 0001830214
- Fiscal year ends
- Dec
- Filings held
- 265 since 2020
- 8-K events
- 67
- Shares short
- 8.3M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
5 years · US$ millions
| Fiscal period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Period ending | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K | 10-K | 10-K |
| Report filed | 29 Mar 2022 | 13 Mar 2023 | 29 Feb 2024 | 25 Feb 2025 | 26 Feb 2026 |
| Revenue | 314M | 478M | 251M | 227M | 170M |
| Cost of revenue | 130M | 204M | 54M | 39M | 32M |
| Gross profit | 184M | 273M | 197M | 188M | 139M |
| Gross margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research and development | 1,150M | 1,053M | 581M | 424M | 244M |
| Operating income | -1,828M | -2,209M | -864M | -560M | -315M |
| Operating margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Profit before tax | -1,838M | -2,121M | -893M | -548M | -314M |
| Income tax | -1M | -15M | -0M | -0M | -1M |
| Net income | -1,830M | -2,105M | -893M | -547M | -313M |
| Net margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| Earnings per share, diluted | -55.60 | -50.00 | -18.40 | -10.54 | -5.64 |
| Diluted shares | 34M | 42M | 49M | 52M | 55M |
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $714.5M
- Price
- $11.21
- Price to book
- 1.70×
- Enterprise value
- $630.0M
- Market cap / sales
- 6.39×
- 52-week high
- $14.99
- 52-week low
- $5.48
Profitability
- Operating margin
- -259.9%
- Net margin
- -260.0%
- FCF margin
- -156.3%
- ROE
- -69.2%
- ROE, 3-year average
- -73.1%
- ROCE
- -69.2%
Growth
- Sales growth, TTM
- -51.5%
- Sales CAGR, 3 years
- -29.1%
- Sales CAGR, 5 years
- 17.3%
- Price, 1 year
- -6.6%
- Price CAGR, 3 years
- -41.1%
- Price CAGR, 5 years
- -54.1%
Balance sheet
- Cash and equivalents
- $84.5M
- Borrowings
- $0
- Net debt
- -$84.5M
- Debt to equity
- 0.00×
- Shareholders' equity
- $420.3M
- Total assets
- $990.0M
- Net debt change, 1 year
- $119.0M
Shareholders
- Shares outstanding
- 63,711,102
- Share count, last 12 months
- 14.9%
- Years FCF margin > 20%, of 5
- 0
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
By product, FY2025
- Cell Engineering$132.7M 78.0%
- Service$37.4M 22.0%
3 years held, FY2023 to FY2025
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 29 Oct 2026 | 29 Oct, 4:06 PM ET | 8-K | Investor update | 7.01, 9.01 | |
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 | ||
| 30 Jul 2026 | 8-K | Investor update | 7.01, 9.01 | ||
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07 | ||
| 7 May 2026 | 8-K | Results | 2.02, 9.01 | ||
| 7 Apr 2026 | 8-K | Deal completed | 2.01, 9.01 | ||
| 27 Feb 2026 | 8-K | Material agreement | 1.01, 9.01 | ||
| 26 Feb 2026 | 8-K | Results | 2.02 | ||
| 23 Dec 2025 | 8-K | Leadership changeOther events | 5.02, 8.01 | ||
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 | ||
| 4 Sep 2025 | 8-K | Material agreement | 1.01, 9.01 | ||
| 29 Aug 2025 | 8-K | Other events | 8.01 | ||
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 | ||
| 13 Jun 2025 | 8-K | Shareholder vote | 5.07 | ||
| 21 May 2025 | 8-K | Leadership changeInvestor update | 5.02, 7.01, 9.01 | ||
| 6 May 2025 | 8-K | Results | 2.02, 9.01 | ||
| 25 Feb 2025 | 8-K | Results | 2.02, 9.01 | ||
| 12 Nov 2024 | 8-K | ResultsLeadership change | 2.02, 5.02, 9.01 | ||
| 4 Sep 2024 | 8-K | Delisting noticeOther events | 3.01, 8.01 | ||
| 19 Aug 2024 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 | ||
| 15 Aug 2024 | 8-K | Shareholder voteOther events | 5.07, 8.01 | ||
| 8 Aug 2024 | 8-K/A | ResultsRestructuring | 2.02, 2.05, 9.01 | ||
| 24 Jun 2024 | 8-K/A | Restructuring | 2.05 | ||
| 14 Jun 2024 | 8-K | Shareholder vote | 5.07 | ||
| 13 May 2024 | 8-K | Delisting noticeInvestor update | 3.01, 7.01, 9.01 | ||
| 9 May 2024 | 8-K | ResultsRestructuring | 2.02, 2.05, 9.01 | ||
| 14 Mar 2024 | 8-K | Auditor change | 4.01, 9.01 | ||
| 29 Feb 2024 | 8-K | Results | 2.02, 9.01 | ||
| 10 Jan 2024 | 8-K | Results | 2.02, 9.01 | ||
| 8 Nov 2023 | 8-K | Results | 2.02, 9.01 | ||
| 27 Oct 2023 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 | ||
| 3 Oct 2023 | 8-K | Other events | 8.01 | ||
| 29 Aug 2023 | 8-K | Other events | 8.01, 9.01 | ||
| 23 Aug 2023 | 8-K | Other events | 8.01, 9.01 | ||
| 9 Aug 2023 | 8-K | Results | 2.02, 9.01 | ||
| 20 Jun 2023 | 8-K | Shareholder vote | 5.07 | ||
| 10 May 2023 | 8-K | Results | 2.02, 9.01 | ||
| 5 May 2023 | 8-K | Leadership change | 5.02, 9.01 | ||
| 10 Mar 2023 | 8-K | Investor update | 7.01 | ||
| 1 Mar 2023 | 8-K | Results | 2.02, 9.01 | ||
| 27 Jan 2023 | 8-K | Other events | 8.01, 9.01 | ||
| 11 Jan 2023 | 8-K | Results | 2.02, 9.01 | ||
| 18 Nov 2022 | 8-K | Other events | 8.01, 9.01 | ||
| 14 Nov 2022 | 8-K | Results | 2.02, 9.01 | ||
| 19 Oct 2022 | 8-K | Deal completedOther events | 2.01, 8.01, 9.01 | ||
| 4 Oct 2022 | 8-K | Other events | 8.01, 9.01 | ||
| 15 Aug 2022 | 8-K | Results | 2.02, 9.01 | ||
| 4 Aug 2022 | 8-K | Leadership change | 5.02, 9.01 | ||
| 25 Jul 2022 | 8-K | Material agreementOther events | 1.01, 8.01, 9.01 | ||
| 25 Jul 2022 | 8-K | Share saleInvestor update | 3.02, 7.01, 9.01 |
1–50 of 67
8-K events each year
Hover a column for its exact count
051015
'21'25'26
Every filing
The company's filings with the SEC, newest first: 265 held. Insider, fund and large-holder filings have their own tables below.
| 29 Oct 2026 | 8-K | 29 Oct 2026 | 29 Oct, 4:06 PM ET | |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 | ||
| 5 Aug 2026 | 8-K | 5 Aug 2026 | ||
| 30 Jul 2026 | 8-K | 30 Jul 2026 | ||
| 12 Jun 2026 | 8-K | 11 Jun 2026 | ||
| 7 May 2026 | 10-Q | 31 Mar 2026 | ||
| 7 May 2026 | 8-K | 7 May 2026 | ||
| 29 Apr 2026 | ARS | 31 Dec 2025 | ||
| 29 Apr 2026 | DEFA14A | – | ||
| 29 Apr 2026 | DEF 14A | 11 Jun 2026 | ||
| 7 Apr 2026 | 8-K | 3 Apr 2026 | ||
| 27 Feb 2026 | 8-K | 26 Feb 2026 | ||
| 26 Feb 2026 | S-8 | – | ||
| 26 Feb 2026 | 10-K | 31 Dec 2025 | ||
| 26 Feb 2026 | 8-K | 26 Feb 2026 | ||
| 23 Dec 2025 | 8-K | 18 Dec 2025 | ||
| 6 Nov 2025 | 10-Q | 30 Sep 2025 | ||
| 6 Nov 2025 | 8-K | 6 Nov 2025 | ||
| 4 Sep 2025 | 8-K | 4 Sep 2025 | ||
| 29 Aug 2025 | 8-K | 29 Aug 2025 | ||
| 14 Aug 2025 | EFFECT | – | ||
| 12 Aug 2025 | CORRESP | – | ||
| 12 Aug 2025 | UPLOAD | – | ||
| 7 Aug 2025 | S-3 | – | ||
| 7 Aug 2025 | 10-Q | 30 Jun 2025 | ||
| 7 Aug 2025 | 8-K | 7 Aug 2025 | ||
| 13 Jun 2025 | 8-K | 12 Jun 2025 | ||
| 21 May 2025 | 8-K | 19 May 2025 | ||
| 6 May 2025 | 10-Q | 31 Mar 2025 | ||
| 6 May 2025 | 8-K | 6 May 2025 | ||
| 29 Apr 2025 | ARS | 31 Dec 2024 | ||
| 29 Apr 2025 | DEFA14A | – | ||
| 29 Apr 2025 | DEF 14A | 12 Jun 2025 | ||
| 25 Feb 2025 | S-8 | – | ||
| 25 Feb 2025 | 10-K | 31 Dec 2024 | ||
| 25 Feb 2025 | 8-K | 25 Feb 2025 | ||
| 12 Nov 2024 | 10-Q | 30 Sep 2024 | ||
| 12 Nov 2024 | 8-K | 6 Nov 2024 | ||
| 12 Sep 2024 | 25-NSE | – | ||
| 4 Sep 2024 | 8-K | 3 Sep 2024 | ||
| 19 Aug 2024 | 8-K | 19 Aug 2024 | ||
| 15 Aug 2024 | 8-K | 14 Aug 2024 | ||
| 12 Aug 2024 | DEFA14A | – | ||
| 8 Aug 2024 | 10-Q | 30 Jun 2024 | ||
| 8 Aug 2024 | 8-K/A | 9 May 2024 | ||
| 5 Jul 2024 | DEF 14A | 14 Aug 2024 | ||
| 5 Jul 2024 | UPLOAD | – | ||
| 3 Jul 2024 | PRER14A | – | ||
| 3 Jul 2024 | UPLOAD | – | ||
| 28 Jun 2024 | CORRESP | – |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 19 Oct 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 766 | $10.14 | $7.8K | 50,168 | 21 Oct 2026 |
| 19 Oct 2026 | Canton Barry10% owner | Sale outside a trading plan | 18,803 | $10.14 | $190.7K | 356,329 | 21 Oct 2026 |
| 19 Oct 2026 | Canton Barry10% owner | Sale outside a trading plan | 22,369 | $10.14 | $226.9K | 453,951 | 21 Oct 2026 |
| 19 Oct 2026 | Shetty Reshma P.See remarks | Sale outside a trading plan | 22,369 | $10.14 | $226.9K | 453,951 | 21 Oct 2026 |
| 19 Oct 2026 | Shetty Reshma P.See remarks | Sale outside a trading plan | 18,803 | $10.14 | $190.7K | 356,329 | 21 Oct 2026 |
| 19 Oct 2026 | Kelly Jason RSee remarks | Sale outside a trading plan | 45,682 | $10.14 | $463.4K | 129,065 | 21 Oct 2026 |
| 5 Oct 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 2,403 | $15.00 | $36.0K | 49,448 | 7 Oct 2026 |
| 15 Sep 2026 | Henry Christian ODirector | Sale outside a trading plan | 5,000 | $7.08 | $35.4K | 19,310 | 16 Sep 2026 |
| 24 Aug 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 330 | $6.98 | $2.3K | 51,851 | 25 Aug 2026 |
| 17 Jul 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 752 | $7.90 | $5.9K | 51,438 | 20 Jul 2026 |
| 22 May 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 307 | $8.33 | $2.6K | 50,704 | 26 May 2026 |
| 17 Apr 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 324 | $7.95 | $2.6K | 50,268 | 20 Apr 2026 |
| 13 Apr 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 33,171 | $6.41 | $212.8K | 49,849 | 14 Apr 2026 |
| 10 Apr 2026 | Canton Barry10% owner | Sale outside a trading plan | 124,727 | $6.43 | $802.5K | 436,422 | 13 Apr 2026 |
| 10 Apr 2026 | Shetty Reshma P.See remarks | Sale outside a trading plan | 124,727 | $6.43 | $802.5K | 436,422 | 13 Apr 2026 |
| 9 Apr 2026 | Shetty Reshma P.See remarks | Sale outside a trading plan | 13,116 | $6.40 | $83.9K | 338,568 | 10 Apr 2026 |
| 9 Apr 2026 | Canton Barry10% owner | Sale outside a trading plan | 13,116 | $6.40 | $83.9K | 338,568 | 10 Apr 2026 |
| 9 Apr 2026 | Kelly Jason RSee remarks | Sale outside a trading plan | 109,767 | $6.40 | $702.2K | 316,483 | 10 Apr 2026 |
| 8 Apr 2026 | Shetty Reshma P.See remarks | Sale outside a trading plan | 13,155 | $6.93 | $91.2K | 351,684 | 10 Apr 2026 |
| 8 Apr 2026 | Canton Barry10% owner | Sale outside a trading plan | 13,155 | $6.93 | $91.2K | 351,684 | 10 Apr 2026 |
| 8 Apr 2026 | Kelly Jason RSee remarks | Sale outside a trading plan | 97,015 | $6.93 | $672.3K | 426,250 | 10 Apr 2026 |
| 16 Mar 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 708 | $6.74 | $4.8K | 9,099 | 18 Mar 2026 |
| 20 Jan 2026 | Coen Steven P.See remarks | Sale outside a trading plan | 972 | $8.92 | $8.7K | 8,321 | 22 Jan 2026 |
| 15 Dec 2025 | Coen Steven P.See remarks | Sale outside a trading plan | 736 | $8.89 | $6.5K | 7,488 | 16 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 19 Oct 2026 | Coen Steven P.Officer | 766 | $7.8K | 19 Oct 2026 |
| 19 Oct 2026 | Che AustinOfficer | 2,200 | $22.8K | 19 Oct 2026 |
| 19 Oct 2026 | Che AustinOfficer | 16,058 | $162.9K | 19 Oct 2026 |
| 19 Oct 2026 | Canton BarryOfficer | 18,803 | $190.7K | 19 Oct 2026 |
| 19 Oct 2026 | Shetty Reshma P.Officer, Director | 22,369 | $226.9K | 19 Oct 2026 |
| 19 Oct 2026 | Kelly Jason ROfficer, Director | 45,682 | $463.3K | 19 Oct 2026 |
| 5 Oct 2026 | Coen Steven P.Officer | 2,403 | $36.0K | 5 Oct 2026 |
| 17 Sep 2026 | Che AustinOfficer | 2,200 | $16.0K | 17 Sep 2026 |
| 15 Sep 2026 | HENRY CHRISTIAN ODirector | 5,000 | $35.4K | 15 Sep 2026 |
| 24 Aug 2026 | Coen Steven P.Officer | 330 | $2.3K | 24 Aug 2026 |
| 17 Aug 2026 | Che AustinOfficer | 2,200 | $14.7K | 17 Aug 2026 |
| 17 Jul 2026 | Coen Steven P.Officer | 752 | $5.9K | 17 Jul 2026 |
| 10 Jun 2026 | Che AustinOfficer | 2,200 | $17.7K | 10 Jun 2026 |
| 22 May 2026 | Coen Steven P.Officer | 307 | $2.6K | 22 May 2026 |
| 13 May 2026 | Che AustinOfficer | 2,200 | $18.2K | 13 May 2026 |
| 17 Apr 2026 | Coen Steven P.Officer | 324 | $2.6K | 17 Apr 2026 |
| 15 Apr 2026 | Che AustinOfficer | 2,200 | $17.1K | 15 Apr 2026 |
| 13 Apr 2026 | Coen Steven P.Officer | 33,171 | $212.8K | 13 Apr 2026 |
| 13 Apr 2026 | Che AustinOfficer | 40,893 | $262.3K | 13 Apr 2026 |
| 10 Apr 2026 | Shetty Reshma P.Officer, Director | 124,727 | $802.5K | 10 Apr 2026 |
| 9 Apr 2026 | Canton BarryOfficer | 13,116 | $83.9K | 9 Apr 2026 |
| 9 Apr 2026 | Kelly Jason ROfficer, Director | 109,767 | $702.2K | 9 Apr 2026 |
| 8 Apr 2026 | Canton BarryOfficer | 13,155 | $91.2K | 8 Apr 2026 |
| 8 Apr 2026 | Kelly Jason ROfficer, Director | 97,015 | $672.3K | 8 Apr 2026 |
| 16 Mar 2026 | Coen Steven P.Officer | 708 | $4.8K | 16 Mar 2026 |
| 11 Mar 2026 | Che AustinOfficer | 2,200 | $13.9K | 11 Mar 2026 |
| 4 Feb 2026 | Che AustinOfficer | 2,200 | $19.4K | 4 Feb 2026 |
| 20 Jan 2026 | Coen Steven P.Officer | 972 | $8.7K | 20 Jan 2026 |
| 7 Jan 2026 | Che AustinOfficer | 2,200 | $20.2K | 7 Jan 2026 |
| 15 Dec 2025 | Coen Steven P.Officer | 736 | $6.5K | 15 Dec 2025 |
| 10 Dec 2025 | Che AustinOfficer | 2,200 | $21.0K | 10 Dec 2025 |
| 12 Nov 2025 | Che AustinOfficer | 2,200 | $18.7K | 12 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 30 Jul 2026 | BlackRock, Inc. | 13G amended | 7.7% | 4.1M |
| 15 May 2026 | VIKING GLOBAL INVESTORS LP | 13G amended | 7.1% | 3.6M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 5 Feb 2026 | BAILLIE GIFFORD & CO | 13G amended | 4.93% | 2.4M |
| 14 Nov 2025 | Cascade Investment, L.L.C. | 13G amended | 7.5% | 3.6M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 8.3M | +13.38% | 1.88 |
| 30 Sep 2026 | 7.3M | +2.08% | 2.67 |
| 15 Sep 2026 | 7.2M | +4.39% | 7.2 |
| 31 Aug 2026 | 6.9M | +22.67% | 5.49 |
| 14 Aug 2026 | 5.6M | +5.26% | 4.25 |
| 31 Jul 2026 | 5.3M | +2.09% | 6.67 |
| 15 Jul 2026 | 5.2M | +0.93% | 4.96 |
| 30 Jun 2026 | 5.2M | +5.15% | 4.02 |
| 15 Jun 2026 | 4.9M | +7.57% | 3.31 |
| 29 May 2026 | 4.6M | +0.82% | 4.89 |
1–10 of 122
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
202
quarter to 30 Jun 2026
Added or new
94
since 31 Mar 2026
Trimmed
39
in the quarter
Largest holder
BlackRock, Inc.
$42.4M
The 60 largest of 202 funds, by value
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.this company | $714.5M | $111.9M | -51.5% | -259.9% | -260.0% | -69.2% | – | – |
| Amgen Inc. | $252.0B | $38.1B | 9.1% | 30.0% | 23.0% | 74.8% | 29.0× | 20.9× |
| Gilead Sciences, Inc. | $212.0B | $31.0B | 6.5% | -7.6% | -12.5% | -29.6% | – | – |
| Moderna, Inc. | $88.5B | $2.2B | -27.6% | -149.0% | -141.4% | -46.6% | – | – |
| argenx SE | $55.3B | $4.2B | 89.9% | – | – | 17.6% | 45.6× | – |
| Biogen Inc. | $37.5B | $10.3B | 2.3% | 4.3% | 3.4% | 1.8% | 108.4× | 33.1× |
| BioNTech SE | $22.1B | $3.2B | 4.3% | -49.0% | -39.6% | -5.9% | – | – |
| Exelixis, Inc. | $17.0B | $2.5B | 9.1% | 40.2% | 35.5% | 48.3% | 20.8× | 16.2× |
| Halozyme Therapeutics, Inc. | $14.9B | $1.7B | 41.2% | 35.9% | 24.9% | 288.1% | 39.1× | 27.6× |
| Neurocrine Biosciences Inc. | $14.9B | $3.4B | 34.4% | 23.6% | 20.9% | 19.1% | 21.4× | 17.2× |
| Bio-Techne Corp. | $11.3B | $1.2B | -0.4% | 20.7% | 15.0% | 8.6% | 63.2× | 32.3× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence